Progress and Trend of CAR-T and PD-1 Blockade in the Treatment of Acute Myeloid Leukemia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1069-1074, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-827159
ABSTRACT
Abstract Acute myeloid leukemia (AML) is a malignant clonal proliferative hematological tumor that originates from hematopoietic stem progenitor cells. Traditional chemotherapy can achieve complete remission in most patients, but so far, only allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way to cure AML. Recurrence, drug resistance, and transplant-related deaths remain a key issue for AML treatment. Therefore, finding new treatments to improve the prognosis of patients with AML is urgently needed. In recent years, the emergence of new immunotherapy has revolutionized the concept of cancer treatment in the past few decades. Cellular immunotherapy represented by chimeric-antigen receptor T cell (CAR-T) and immunological detection point inhibitor represented by PD-1 blockade have achieved remarkable effects in hematological malignancies. This article mainly reviews the recent research progress of CAR-T and PD-1 blockade in the clinical treatment of AML.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Leukemia, Myeloid, Acute
/
Immunotherapy, Adoptive
/
Hematopoietic Stem Cell Transplantation
/
Programmed Cell Death 1 Receptor
/
Receptors, Chimeric Antigen
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS